(Q42652135)

4 November 2017

title

Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus (English)

1 reference

systemic lupus erythematosus

4 November 2017

1 reference

1 reference

1

Joan T Merrill

1 reference

4 November 2017

6

Cynthia Aranow

1 reference

4 November 2017

2

Ellen M Ginzler

1 reference

4 November 2017

Daniel J Wallace

3

1 reference

4 November 2017

James D McKay

4

1 reference

4 November 2017

Jeffrey R Lisse

5

1 reference

4 November 2017

Frank R Wellborne

7

1 reference

4 November 2017

Michael Burnette

8

1 reference

4 November 2017

John Condemi

9

1 reference

4 November 2017

Z John Zhong

10

1 reference

4 November 2017

Lilia Pineda

11

1 reference

4 November 2017

Jerry Klein

12

1 reference

4 November 2017

William W Freimuth

13

1 reference

4 November 2017

LBSL02/99 Study Group

14

1 reference

4 November 2017

language of work or name

1 reference

1 October 2012

1 reference

4 November 2017

published in

Arthritis & Rheumatology

1 reference

4 November 2017

volume

64

1 reference

4 November 2017

issue

10

1 reference

4 November 2017

page(s)

3364-3373

1 reference

Systemic lupus erythematosus.

4 November 2017

cites work

1 reference

Treatment of lupus with corticosteroids

21 January 2018

1 reference

The relationship between cancer and medication exposures in systemic lupus erythaematosus: a case-cohort study

21 January 2018

1 reference

Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents

21 January 2018

1 reference

Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients

21 January 2018

1 reference

Serious infections in British patients with systemic lupus erythematosus: hospitalisations and mortality

21 January 2018

1 reference

Two aspects of the clinical and humanistic burden of systemic lupus erythematosus: mortality risk and quality of life early in the course of disease

21 January 2018

1 reference

Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus

21 January 2018

1 reference

Accumulation of coronary artery disease risk factors over three years: data from an international inception cohort

21 January 2018

1 reference

An international cohort study of cancer in systemic lupus erythematosus

21 January 2018

1 reference

Hodgkin's lymphoma in systemic lupus erythematosus

21 January 2018

1 reference

Cancer risk in a cohort of patients with systemic lupus erythematosus (SLE) in California

21 January 2018

1 reference

Mortality in systemic lupus erythematosus

21 January 2018

1 reference

BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator

21 January 2018

1 reference

Generation and characterization of LymphoStat‐B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator

21 January 2018

1 reference

Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases.

21 January 2018

1 reference

Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus

21 January 2018

1 reference

Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus

21 January 2018

1 reference

A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus

21 January 2018

1 reference

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

21 January 2018

1 reference

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

21 January 2018

1 reference

Update on immunotherapy for systemic lupus erythematosus--what's hot and what's not!

21 January 2018

1 reference

Biologics in the treatment of systemic lupus erythematosus

21 January 2018

1 reference

Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis

21 January 2018

1 reference

Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial

21 January 2018

1 reference

Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis

21 January 2018

1 reference

Induction and maintenance therapy for lupus nephritis: a systematic review and meta-analysis

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/ART.34564

1 reference

4 November 2017

1 reference